Although clinical data on PARPi use in IDH1 mutated CCA is lacking, olaparib is currently being tested in patients with advanced glioma or cholangiocarcinoma with IDH1/2 mutations [NCT03212274]. The gene discussed is IDH1; the disease is cholangiocarcinoma.